Form 4: Guardant Health CLO Vests, Sells Shares for Tax

Guardant Health's Chief Legal Officer, John G. Saia, vested 1,019 restricted stock units and sold 535 shares to cover tax obligations.

Summary

• John G. Saia, Chief Legal Officer of Guardant Health, Inc. (GH), reported changes in his beneficial ownership.
• On September 15, 2025, 1,019 Restricted Stock Units (RSUs) vested and converted into common stock.
• Concurrently, 535 shares of common stock were disposed of at a price of $54.79 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Saia directly owns 45,432 shares of Guardant Health common stock.
• He also holds 3,059 unvested Restricted Stock Units.
• The vested RSUs are part of an award granted on June 9, 2023, with a three-year vesting schedule, where 33% vested on June 15, 2024, and the remainder vests quarterly.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving RSU vesting and tax-related share sales. It's a neutral event, indicating ongoing executive compensation and alignment, but not significant positive or negative news for the company's operations or financial health.

Positives

• Vesting of 1,019 Restricted Stock Units indicates continued long-term incentive alignment for the Chief Legal Officer.
• The officer retains a significant number of common shares (45,432) and unvested RSUs (3,059), demonstrating ongoing equity interest in the company.

Negatives

• A portion of the vested shares (535 shares) was sold to cover tax liabilities, which is a common practice but reduces the direct equity holding from the vesting event.

Future Outlook

The remaining 67% of the Restricted Stock Unit award, granted on June 9, 2023, is scheduled to vest in equal quarterly installments over the two-year period following June 15, 2024, with the reported transaction on September 15, 2025, representing one such installment.

Industry Context

This filing represents a routine insider transaction related to equity compensation, common across publicly traded companies, particularly in the biotechnology and healthcare sectors where long-term incentives like RSUs are prevalent to align management interests with shareholder value.

Comparison to Industry Standards

• The vesting and subsequent sale of shares for tax purposes is a standard practice for equity compensation in the U.S. market.
• The specific value of the shares ($54.79) reflects Guardant Health's market valuation at the time of the transaction, which can be compared to peer companies like Exact Sciences (EXAS) or Natera (NTRA) in the precision oncology and diagnostics space, though this filing does not provide comparative financial performance data.

Related Party Transactions

• The disposition of 535 shares to the company for tax withholding purposes is a related party transaction, common in equity compensation plans.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting is offset by continued management alignment.
• Employees: No direct impact.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• Future quarterly vesting installments of the remaining 3,059 Restricted Stock Units will occur over the next two years, following the schedule of the award granted on June 9, 2023.

Key Dates

Recommendation

This Form 4 filing details a routine vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations by a Chief Legal Officer. Such transactions are standard practice for executive compensation and do not provide new material information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The insider retains a substantial equity stake, indicating continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing does not present a catalyst for significant price movement or a re-evaluation of the company's fundamentals.

Keywords

Guardant Health, GH, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, John G. Saia, Chief Legal Officer, Equity Compensation, Stock Ownership